{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:17:09Z","timestamp":1777861029268,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Acumen Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09656-w","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:34:27Z","timestamp":1774262067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer\u2019s disease: a qualitative interview study"],"prefix":"10.1186","volume":"27","author":[{"given":"Elizabeth","family":"Merikle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Presnall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Feaster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"Moxon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Siemers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Kerwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Cline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"4","key":"9656_CR1","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3233\/JAD-190146","volume":"69","author":"C Clement","year":"2019","unstructured":"Clement C, Selman LE, Kehoe PG, Howden B, Lane JA, Horwood J. Challenges to and facilitators of recruitment to an Alzheimer\u2019s disease clinical trial: a qualitative interview study. J Alzheimers Dis. 2019;69(4):1067\u201375.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"9656_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2):e12385.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"9656_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12465","volume":"10","author":"J Cummings","year":"2024","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimers Dement (N Y). 2024;10(2):e12465.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"9656_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01352-0","volume":"15","author":"M Ritchie","year":"2023","unstructured":"Ritchie M, Gillen DL, Grill JD. Estimating attrition in mild-to-moderate Alzheimer\u2019s disease and mild cognitive impairment clinical trials. Alzheimers Res Ther. 2023;15(1):203.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"9656_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/geront\/gnz096","volume":"60","author":"SH Bardach","year":"2019","unstructured":"Bardach SH, Parsons K, Gibson A, Jicha GA. From victimhood to warriors\u201d: super-researchers\u2019 insights into Alzheimer\u2019s disease clinical trial participation motivations. Gerontologist. 2019;60(4):693\u2013703.","journal-title":"Gerontologist"},{"issue":"2","key":"9656_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40520-017-0771-2","volume":"30","author":"SH Bardach","year":"2018","unstructured":"Bardach SH, Holmes SD, Jicha GA. Motivators for Alzheimer\u2019s disease clinical trial participation. Aging Clin Exp Res. 2018;30(2):209\u201312.","journal-title":"Aging Clin Exp Res"},{"key":"9656_CR7","doi-asserted-by":"crossref","unstructured":"Gabel M, Bollinger RM, Coble DW, Grill JD, Edwards DF, Lingler JH, et al. Retaining participants in longitudinal studies of Alzheimer\u2019s disease. J Alzheimers Dis. 2022;87(2):945-55.","DOI":"10.3233\/JAD-215710"},{"issue":"1","key":"9656_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01190-0","volume":"15","author":"L Ottenhoff","year":"2023","unstructured":"Ottenhoff L, Vijverberg EGB, Visser LNC, Verijp M, Prins ND, Van der Flier WM, et al. Experiences of and recommendations on clinical trial design in Alzheimer\u2019s disease from the participant\u2019s point of view: a mixed-methods study in two clinical trial centers in the Netherlands. Alzheimers Res Ther. 2023;15(1):72.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"9656_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","volume":"18","author":"GBD 2016 Dementia Collaborators","year":"2019","unstructured":"GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88\u2013106.","journal-title":"Lancet Neurol"},{"key":"9656_CR10","doi-asserted-by":"crossref","unstructured":"Martinkova J, Quevenco F-C, Karcher H, Ferrari A, Sandset EC, Szoeke C, et al. Proportion of women and reporting of outcomes by sex in clinical trials for Alzheimer disease: a systematic review and meta-analysis. JAMA Network Open. 2021;4(9):e2124124-e.","DOI":"10.1001\/jamanetworkopen.2021.24124"},{"key":"9656_CR11","doi-asserted-by":"crossref","unstructured":"Siemers E, Feaster T, Sethuraman G, Sundell K, Skljarevski V, Cline EN, et al. INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer\u2019s disease. J Prev Alzheimer\u2019s Dis. 2025;12(1):100005.","DOI":"10.1016\/j.tjpad.2024.100005"},{"key":"9656_CR12","unstructured":"U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) patient-focused drug development: methods to identify what is important to patients guidance for industry, Food and Drug administration staff, and other stakeholders. Silver Spring, MD. 2022."},{"key":"9656_CR13","unstructured":"Lumivero. NVivo (Version 14). 2023."},{"issue":"8","key":"9656_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity- -establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1- -eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"key":"9656_CR15","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V, Terry G, Hayfield N. Thematic analysis. In: Liamputtong P (ed). Handbook of Research Methods in Health and Social Sciences. Singapore: Springer; 2019. pp. 843\u201360.","DOI":"10.1007\/978-981-10-5251-4_103"},{"key":"9656_CR16","doi-asserted-by":"crossref","unstructured":"Guest G, MacQueen K, Namey E. Applied thematic analysis. Thousand Oaks, California. 2012. 2024\/10\/07.","DOI":"10.4135\/9781483384436"},{"issue":"1","key":"9656_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/160940690600500107","volume":"5","author":"J Fereday","year":"2006","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods. 2006;5(1):80\u201392.","journal-title":"Int J Qual Methods"},{"issue":"5","key":"9656_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232076","volume":"15","author":"G Guest","year":"2020","unstructured":"Guest G, Namey E, Chen M. A simple method to assess and report thematic saturation in qualitative research. PLoS One. 2020;15(5):e0232076.","journal-title":"PLoS One"},{"issue":"3","key":"9656_CR19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jagp.2018.10.016","volume":"27","author":"CG Cox","year":"2019","unstructured":"Cox CG, Ryan BAM, Gillen DL, Grill JD. A preliminary study of clinical trial enrollment decisions among people with mild cognitive impairment and their study partners. Am J Geriatr Psychiatry. 2019;27(3):322\u201332.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"9656_CR20","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1046\/j.1532-5415.2002.50615.x","volume":"50","author":"JHT Karlawish","year":"2002","unstructured":"Karlawish JHT, Casarett DJ, James BD. Alzheimer\u2019s disease patients\u2019 and caregivers\u2019 capacity, competency, and reasons to enroll in an early-phase Alzheimer\u2019s disease clinical trial. J Am Geriatr Soc. 2002;50(12):2019\u201324.","journal-title":"J Am Geriatr Soc"},{"key":"9656_CR21","doi-asserted-by":"crossref","unstructured":"Raman R, Quiroz YT, Langford O, Choi J, Ritchie M, Baumgartner M, et al. Disparities by race and ethnicity among adults recruited for a preclinical Alzheimer disease trial. JAMA Network Open. 2021;4(7):e2114364-e.","DOI":"10.1001\/jamanetworkopen.2021.14364"},{"issue":"3","key":"9656_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12402","volume":"9","author":"J Savold","year":"2023","unstructured":"Savold J, Cole M, Thorpe RJ Jr. Barriers and solutions to Alzheimer\u2019s disease clinical trial participation for Black Americans. Alzheimers Dement (N Y). 2023;9(3):e12402.","journal-title":"Alzheimers Dement (N Y)"},{"key":"9656_CR23","doi-asserted-by":"crossref","unstructured":"Moxon R, Feaster T, Carroll A, Gan ST, Ziemba S, Price K, Skljarevski V, Sundell KL, Sethuraman G, Hitchcock J, Siemers ER. Recruitment strategies and tactics for INTERCEPT-AD: a phase I trial of A\u03b2 oligomer-targeting ACU193 in early Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2023;19(Suppl. 24):e082860.","DOI":"10.1002\/alz.082860"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09656-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09656-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09656-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:44:09Z","timestamp":1777517049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09656-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9656"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09656-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The INTERCEPT-AD phase 1 clinical study was conducted in accordance with International Council for Harmonisation E6 Good Clinical Practice, the Declaration of Helsinki, and all other applicable regulatory requirements. The protocol and informed consent form were approved by ethics committees for all study sites. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The informed consent document, which was signed by all study participants, included permission for the inclusion of their data in the publication of summary data from the INTERCEPT-AD clinical trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CP and EM were employees of Fortrea, Inc. at the time of study conduct; Fortrea, Inc. received funding from Acumen Pharmaceuticals, Inc. for the conduct of this study.DK is the Founder and President of Kerwin Medical Center, which received contractual payments from Acumen Pharmaceuticals, Inc. as an INTERCEPT-AD study site.TF, RM, and ES are employees of and hold equity in Acumen Pharmaceuticals, Inc.SC is a consultant to Acumen Pharmaceuticals, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"339"}}